Stocks and Investing Stocks and Investing
Mon, June 13, 2022
Sun, June 12, 2022
Fri, June 10, 2022
Thu, June 9, 2022
Wed, June 8, 2022
Tue, June 7, 2022

David Lebowitz Maintained (ARQT) at Buy with Increased Target to $39 on, Jun 7th, 2022


Published on 2024-10-27 21:26:24 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Increased Target from $36 to $39 on, Jun 7th, 2022.

David has made no other calls on ARQT in the last 4 months.



There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Uy Ear of "Mizuho" Maintained at Strong Buy with Decreased Target to $57 on, Thursday, April 7th, 2022